Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals

Neuropsychopharmacology

Volumn 40, Issue 2, 2015, Pages 386-393

  Otte, Christian ^a   Wingenfeld, Katja ^a   Kuehl, Linn K ^a   Kaczmarczyk, Michael ^a   Richter, Steffen ^a   Quante, Arnim ^a   Regen, Francesca ^a   Bajbouj, Malek ^a   Zimmermann Viehoff, Frank ^a   Wiedemann, Klaus ^b   Hinkelmann, Kim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE; MINERALOCORTICOID RECEPTOR; PSYCHOTROPIC AGENT;

ADULT; BLOOD PRESSURE; COGNITION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSIVE DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MEMORY; METABOLISM; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SALIVA; SECRETION (PROCESS);

ADULT; BLOOD PRESSURE; COGNITION; CROSS-OVER STUDIES; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; EXECUTIVE FUNCTION; FEMALE; FLUDROCORTISONE; HUMANS; HYDROCORTISONE; MALE; MEMORY; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR PERFORMANCE; PSYCHOTROPIC DRUGS; RECEPTORS, MINERALOCORTICOID; SALIVA;

EID: 84925354531     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.181     Document Type: Article

References (62)

1. Agarwal M, Coupry F, Philippe M (1977). Physiological activity and receptor binding of 9 alpha fluorohydrocortisone. Biochem Biophys Res Commun 78: 747-753.
2. Behnken A, Bellingrath S, Symanczik JP, Rieck MJ, Zavorotnyy M, Domschke K et al (2013). Associations between cognitive performance and cortisol reaction to the DEX/CRH test in patients recovered from depression. Psychoneuroendocrinology 38: 447-454.
3. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM et al (2006). Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proc Natl Acad Sci USA 103: 195-200.
4. Binder EB, Nemeroff CB (2010). The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol Psychiatry 15: 574-588.
5. Bogdan R, Williamson DE, Hariri AR (2012). Mineralocorticoid receptor Iso/Val (rs5522) genotype moderates the association between previous childhood emotional neglect and amygdala reactivity. Am J Psychiatry 169: 515-522.
6. Brinks V, Berger S, Gass P, de Kloet ER, Oitzl MS (2009). Mineralocorticoid receptors in control of emotional arousal and fear memory. Horm Behav 56: 232.
7. Buckley TM, Mullen BC, Schatzberg AF (2007). The acute effects of a mineralocorticoid receptor (MR) agonist on nocturnal hypothalamic-adrenal-pituitary (HPA) axis activity in healthy controls. Psychoneuroendocrinology 32: 859.
8. Cornelisse S, Joels M, Smeets T (2011). A randomized trial on mineralocorticoid receptor blockade in men: effects on stress responses, selective attention, and memory. Neuropsychopharmacology 36: 2720-2728.
9. de Kloet ER (2013). Functional profile of the binary brain corticosteroid receptor system: mediating, multitasking, coordinating, integrating. Eur J Pharmacol 719: 53-62.
10. Ferguson D, Sapolsky R (2008). Overexpression of mineralocorticoid and transdominant glucocorticoid receptor blocks the impairing effects of glucocorticoids on memory. Hippocampus 18: 1103-1111.
11. Gold PW, Chrousos GP (2013). Melancholic and atypical subtypes of depression represent distinct pathophysiological entities: CRH, neural circuits, and the diathesis for anxiety and depression. Mol Psychiatry 18: 632-634.
12. Gomez RG, Fleming SH, Keller J, Flores B, Kenna H, DeBattista C et al (2006). The neuropsychological profile of psychotic major depression and its relation to cortisol. Biolo Psychiatry 60: 472.
13. Groch S, Wilhelm I, Lange T, Born J (2013). Differential contribution of mineralocorticoid and glucocorticoid receptors to memory formation during sleep. Psychoneuroendocrinology 38: 2962-2972.
14. Grossmann C, Scholz T, Rochel M, Bumke-Vogt C, Oelkers W, Pfeiffer AF et al (2004). Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocortcoid properties. European J Endocrinology 151: 397-406.
15. Harris AP, Holmes MC, de Kloet ER, Chapman KE, Seckl JR (2013). Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour. Psychoneuroendocrinology 38: 648-658.
16. Henckens MJ, van Wingen GA, Joels M, Fernandez G (2011). Timedependent corticosteroid modulation of prefrontal working memory processing. Proc Natl Acad Sci USA 108: 5801-5806.
17. Herbert J (2013). Cortisol and depression: three questions for psychiatry. Psychol Med 43: 449-469.
18. Hinkelmann K, Moritz S, Botzenhardt J, Riedesel K, Wiedemann K, Kellner M et al (2009). Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 66: 879-885.
19. Hinkelmann K, Muhtz C, Dettenborn L, Agorastos A, Moritz S, Wingenfeld K et al (2013). Association between cortisol awakening response and memory function in major depression. Psychol Med 43: 2255-2263.
20. Holsboer F, Ising M (2010). Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol 61: 81-109 C101-111.
21. Joels M, Karst H, DeRijk R, de Kloet ER (2008). The coming out of the brain mineralocorticoid receptor. Trends Neurosci 31: 1-7.
22. Joëls M, Karst H, DeRijk R, de Kloet ER (2008). The coming out of the brain mineralocorticoid receptor. Trends Neurosci 31: 1.
23. Joels M, Pasricha N, Karst H (2013). The interplay between rapid and slow corticosteroid actions in brain. Eur J Pharmacol 719: 44-52.
24. Joels M, Sarabdjitsingh RA, Karst H (2012). Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev 64: 901-938.
25. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2009). Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 194: 342-349.
26. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ (2013). The role of mineralocorticoid receptor function in treatment-resistant depression. J Psychopharmacol 27: 1169-1179.
27. Khaksari M, Rashidy-Pour A, Vafaei AA (2007). Central mineralocorticoid receptors are indispensable for corticosterone-induced impairment of memory retrieval in rats. Neuroscience 149: 729-738.
28. Klok MD, Alt SR, Irurzun Lafitte AJ, Turner JD, Lakke EA, Huitinga I et al (2011a). Decreased expression of mineralocorticoid receptor mRNA and its splice variants in postmortem brain regions of patients with major depressive disorder. J Psychiatr Res 45: 871-878.
29. Klok MD, Giltay EJ, Van der Does AJ, Geleijnse JM, Antypa N, Penninx BW et al (2011b). A common and functional mineralocorticoid receptor haplotype enhances optimism and protects against depression in females. Transl Psychiatry 1: e62.
30. Krogh J, Videbech P, Renvillard SG, Garde AH, Jorgensen MB, Nordentoft M (2012). Cognition and HPA axis reactivity in mildly to moderately depressed outpatients: a case-control study. Nord J Psychiatry 66: 414-421.
31. Lai M, Horsburgh K, Bae SE, Carter RN, Stenvers DJ, Fowler JH et al (2007). Forebrain mineralocorticoid receptor overexpression enhances memory, reduces anxiety and attenuates neuronal loss in cerebral ischaemia. Eur J Neurosci 25: 1832-1842.
32. Lembke A, Gomez R, Tenakoon L, Keller J, Cohen G, Williams GH et al (2013). The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. Psychoneuroendocrinology 38: 115-121.
33. Lezak M (1995). Neuropsychological Assessment. 3rd edn Oxford University Press: New York, NY.
34. Maggio N, Segal M (2007). Striking variations in corticosteroid modulation of long-term potentiation along the septotemporal axis of the hippocampus. J Neurosci 27: 5757-5765.
35. Medina A, Seasholtz AF, Sharma V, Burke S, Bunney W Jr., Myers RM et al (2013). Glucocorticoid and mineralocorticoid receptor expression in the human hippocampus in major depressive disorder. J Psychiatr Res 47: 307-314.
36. Miller (2008). Adrenocorticoids. In: Williams DA (ed.) Foye's Principles of Medicinal Chemistry. 6th edn, Lippincott Williams & Wilkins, a Wolters Kluwer business: Baltimore, MD, pp 890-891.
37. Muller MB, Zimmermann S, Sillaber I, Hagemeyer TP, Deussing JM, Timpl P et al (2003). Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6: 1100-1107.
38. O'Hara R, Schroder CM, Mahadevan R, Schatzberg AF, Lindley S, Fox S et al (2007). Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry 12: 544.
39. Osterrieth PA (1944). Le test de copie d'une figure complexe; contribution a l'etude de la perception et de la memoire (Test of copying a complex figure; contribution to the study of perception and memory). Archives de Psychologie 30: 206-356.
40. Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K et al (2010a). Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 44: 339-346.
41. Otte C, Hinkelmann K, Moritz S, Yassouridis A, Jahn H, Wiedemann K et al (2010b). Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res 44: 339-346.
42. Otte C, Jahn H, Yassouridis A, Arlt J, Stober N, Maass P et al (2003). The mineralocorticoid receptor agonist, fludrocortisone, inhibits pituitary-adrenal activity in humans after pre-treatment with metyrapone. Life Sci 73: 1835-1845.
43. Otte C, Moritz S, Yassouridis A, Koop M, Madrischewski AM, Wiedemann K et al (2007). Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. Neuropsychopharmacology 32: 232-238.
44. Pariante CM, Lightman SL (2008). The HPA axis in major depression: classical theories and new developments. Trends Neurosci 31: 464.
45. Qi XR, Kamphuis W, Wang S, Wang Q, Lucassen PJ, Zhou JN et al (2013). Aberrant stress hormone receptor balance in the human prefrontal cortex and hypothalamic paraventricular nucleus of depressed patients. Psychoneuroendocrinology 38: 863-870.
46. Qiu S, Champagne DL, Peters M, Catania EH, Weeber EJ, Levitt P et al (2010). Loss of limbic system-associated membrane protein leads to reduced hippocampal mineralocorticoid receptor expression, impaired synaptic plasticity, and spatial memory deficit. Biol Psychiatry 68: 197-204.
47. Reitan RM (1992). Trail Making Test. Manual of Administration and Scoring. Reitan Neuropsychology Laboratory: Tuscon, Arizona, USA.
48. Rimmele U, Besedovsky L, Lange T, Born J (2013). Blocking mineralocorticoid receptors impairs, blocking glucocorticoid receptors enhances memory retrieval in humans. Neuropsychopharmacology 38: 884-894.
49. Rock PL, Roiser JP, Riedel WJ, Blackwell AD (2013). Cognitive impairment in depression: a systematic review and metaanalysis. Psychol Med (e-pub ahead of print).
50. Rozeboom AM, Akil H, Seasholtz AF (2007). Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. Proc Natl Acad Sci USA 104: 4688-4693.
51. Schatzberg AF, Posener JA, DeBattista C, Kalehzan BM, Rothschild AJ, Shear PK (2000). Neuropsychological deficits in psychotic versus nonpsychotic major depression and no mental illness. Am J Psychiatry 157: 1095-1100.
52. Schwabe L, Schachinger H, de Kloet ER, Oitzl MS (2010). Corticosteroids operate as a switch between memory systems. J Cogn Neurosci 22: 1362-1372.
53. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59: 22-33.
54. ter Horst JP, van der Mark MH, Arp M, Berger S, de Kloet ER, Oitzl MS (2012). Stress or no stress: mineralocorticoid receptors in the forebrain regulate behavioral adaptation. Neurobiol Learn Mem 98: 33-40.
55. Trivedi MH, Greer TL (2014). Cognitive dysfunction in unipolar depression: implications for treatment. J Affect Disord 152-154: 19-27.
56. van Ast VA, Cornelisse S, Meeter M, Joels M, Kindt M (2013). Time-dependent effects of cortisol on the contextualization of emotional memories. Biol Psychiatry 74: 809-816.
57. Wagner S, Doering B, Helmreich I, Lieb K, Tadic A (2012). A metaanalysis of executive dysfunctions in unipolar major depressive disorder without psychotic symptoms and their changes during antidepressant treatment. Acta Psychiatr Scand 125: 281-292.
58. Wang XD, Rammes G, Kraev I, Wolf M, Liebl C, Scharf SH et al (2011). Forebrain CRF(1) modulates early-life stressprogrammed cognitive deficits. J Neurosci 31: 13625-13634.
59. Watson S, Gallagher P, Porter RJ, Smith MS, Herron LJ, Bulmer S et al (2012). A randomized trial to examine the effect of mifepristone on neuropsychological performance and mood in patients with bipolar depression. Biol Psychiatry 72: 943-949.
60. Wingenfeld K, Kueh LK, Janke K, Hinkelmann K, Dziobek I, Fleischer J et al (2014). Enhanced emotional empathy after mineralocorticoid receptor stimulation in women with borderline personality disorder and healthy women. Neuropsychopharmacology 39: 1799-1804.
61. Wingenfeld K, Wolf OT (2011). HPA-axis alterations in mental disorders: impact on memory and its relevance for therapeutic interventions. CNS Neurosci Ther 17: 714-722.
62. Young EA, Lopez JF, Murphy-Weinberg V, Watson SJ, Akil H (2003). Mineralocorticoid receptor function in major depression. Arch Gen Psychiatry 60: 24-28.